Back to search
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
This is an observational study in which medical records of Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC), who received treat…
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prost…
The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with…
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses…
This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's p…
This is an observational study in which only data are collected from participants receiving their usual treatment. In this study, data will be collected and st…
This is a prospective, interventional, non-randomized, phase 2 study to assess oncologic outcomes of metastatic hormone-sensitive prostate cancer (mCSPC) patien…